| 1 | Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. (Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, Trollinger B, Shah P, Ambinder R, Neofytos D, Ostrander D, Forman M, Valsamakis A) Transplantation 2016 Oct;100(10):e74-80 155 Citations |
| 1 | In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action. (Cai H, Kapoor A, He R, Venkatadri R, Forman M, Posner GH, Arav-Boger R) Antimicrob Agents Chemother 2014;58(2):986-94 53 Citations |
| 1 | Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection. (Justrabo E, Zanetta G, Martin L, Assem M, Mousson C, Maurice-Estepa L, Rifle G, Tanter Y) Histopathology 1999 Apr;34(4):365-9 18 Citations |
| 2 | Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo. (Drobyski WR, Dunne WM, Burd EM, Knox KK, Ash RC, Horowitz MM, Flomenberg N, Carrigan DR) J Infect Dis 1993 Mar;167(3):735-9 229 Citations |
| 1 | Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. (Drobyski WR, Knox KK, Carrigan DR, Ash RC) Transplantation 1991 Jul;52(1):155-7 41 Citations |
| 1 | Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. (Knox KK, Drobyski WR, Carrigan DR) Lancet 1991 May 25;337(8752):1292-3 99 Citations |
© 2026 Clinical & Translational Science Institute